Manufacturing and Facilities 2023 eBook
Read the article:
Read the ebook:
Publication|Articles|November 15, 2023
- Manufacturing and Facilities, November 2023 eBook
- Volume 2023 eBook
- Issue 4
- Pages: 26–28
Update on Facilities and Manufacturing Trends
Author(s)Daria G. Husni
A look into the latest developments in biopharmaceutical manufacturing and facilities.
Advertisement
As the biopharmaceutical industry moves into the end of 2023, biopharmaceutical companies should take stock of the latest developments in biopharmaceutical manufacturing and facilities. Over the past few months, manufacturing has seen many facility expansions and openings throughout the globe, partnerships for outsourcing services, and various acquisitions and expansions of manufacturing companies.
Read
About the author
Daria G. Husni is assistant editor with BioPharm International.
Article details
BioPharm International
eBook: Manufacturing and Facilities
November 2023
Pages: 26–28
Citation
When referring to this article, please cite it as Husni, D. Update on Facilities and Manufacturing Trends. BioPharm International’s Manufacturing and Facilities eBook. November 2023.
Articles in this issue
almost 3 years ago
De-Risking Sterile Pharma Manufacture with SUTsalmost 3 years ago
Tech Transfer and Regulatory Compliancealmost 3 years ago
A Look at Supply Chain for Scale Upalmost 3 years ago
Sustainability Using Zero-Carbon Biopharma Facilitiesalmost 3 years ago
Oligonucleotide Production FacilitiesAdvertisement
Related to this article
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.
Samsung Biologics signed a $262 million contract manufacturing agreement with an undisclosed European pharmaceutical company, extending production commitments through 2033 and lifting the CDMO's cumulative contract value past $21.9 billion.
Laru-zova helped 31% of high-dose patients gain 15+ letters of vision, representing the first pivotal trial to succeed in treating XLRP.
mAbxience and Sandoz are targeting a $5.7 billion market with a proposed emicizumab biosimilar for hemophilia A.
FDA's consumer safety officer, Jason Chancey, detailed real inspection findings, such as taped gaskets and delayed retesting, behind sterile facility deficiencies.
Insilico's Longevity Vaccines use circular mRNA to arm T cells against aging's earliest culprit cells, starting with immune rejuvenation.
Tambotatug pelitecan (Tam-Peli), a B7-H3-targeted antibody-drug conjugate, is the second of at least three B7-H3-targeted ADCs to post positive late-stage data in relapsed small-cell lung cancer this year.
Phio's PH-762 posted a 70% response rate in skin cancer, supporting its FDA briefing package for a planned phase 2b trial.
Advertisement
Advertisement